Press releaseACCESS Newswire
Valion Bio
VBIO · NASDAQ
$1.19+$0.0254 (+2.18%)TodayMarket closed ·
Prev close $1.16
Latest news
- Press releaseACCESS Newswire
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
- Press releaseGlobe Newswire
3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours
- Press releaseACCESS Newswire
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
- Press releaseACCESS Newswire
Valion Bio Announces Changes to Management and Board of Directors
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseACCESS Newswire
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseACCESS Newswire
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury
- News
Ukraine's Ministry Of Health Accepts Valion Bio's Regulatory Dossier For Entolimod For Formal Review Under Regulatory Equivalence Pathway
- Press releasePRNewswire
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
- Press releasePRNewswire
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releasePRNewswire
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
- Press releasePRNewswire
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releasePRNewswire
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
- Press releasePRNewswire
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
- Press releasePRNewswire
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
- Press releasePRNewswire
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
- Press releasePRNewswire
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
- Press releasePRNewswire
VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION
- Press releasePRNewswire
Valion Bio Appoints Melinda Lackey as General Counsel
- Press releasePRNewswire
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.